About Fate Therapeutics (NASDAQ:FATE)
Fate Therapeutics, Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company's cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity. Its lead clinical program is ProTmune, which is a programmed immuno-regulatory cell therapy. The Company programs immune cells, such as CD34+ cells, Natural Killer (NK) cells and T cells, by utilizing its cell programming approach. Its adoptive cell therapy programs are based on the Company's ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:FATE
CUSIPN/A
Phone858-875-1800
Debt
Debt-to-Equity Ratio0.19%
Current Ratio9.29%
Quick Ratio9.29%
Price-To-Earnings
Trailing P/E Ratio-11.10
Forward P/E Ratio-12.04
P/E GrowthN/A
Sales & Book Value
Annual Sales$4.11 million
Price / Sales145.34
Cash FlowN/A
Price / CashN/A
Book Value$1.51 per share
Price / Book7.50
Profitability
EPS (Most Recent Fiscal Year)($1.02)
Net Income$-42,950,000.00
Net Margins-1,046.08%
Return on Equity-71.00%
Return on Assets-50.95%
Miscellaneous
Employees80
Outstanding Shares52,770,000
Fate Therapeutics (NASDAQ:FATE) Frequently Asked Questions
What is Fate Therapeutics' stock symbol?
Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE."
How were Fate Therapeutics' earnings last quarter?
Fate Therapeutics (NASDAQ:FATE) released its quarterly earnings results on Monday, March, 5th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.24) by $0.05. The biopharmaceutical company earned $1.03 million during the quarter, compared to analysts' expectations of $1.02 million. Fate Therapeutics had a negative return on equity of 71.00% and a negative net margin of 1,046.08%. The firm's quarterly revenue was up .0% compared to the same quarter last year. View Fate Therapeutics' Earnings History.
When is Fate Therapeutics' next earnings date?
What price target have analysts set for FATE?
8 equities research analysts have issued twelve-month target prices for Fate Therapeutics' shares. Their forecasts range from $7.00 to $20.00. On average, they anticipate Fate Therapeutics' share price to reach $16.1667 in the next twelve months. View Analyst Ratings for Fate Therapeutics.
What are Wall Street analysts saying about Fate Therapeutics stock?
Here are some recent quotes from research analysts about Fate Therapeutics stock:
- 1. HC Wainwright analysts commented, "Fate Announces Updated Data From Phase 1 of PROTECT; Reiterate Neutral Updated ProTmune data shows continued safety and efficacy. Yesterday, Fate Therapeutics announced additional Phase 1 clinical data from PROTECT. As a reminder, Fate is investigating ProTmune, a next-generation hematopoietic cell graft for the prevention of acute graft-versus-host disease (GvHD) in patients undergoing allogeneic hematopoietic cell transplantation (HCT). Data reported at ASH indicated that all subjects (n=7) remained relapse-free, and there were no events of graft failure or serious adverse events (SAEs) that were deemed related to ProTmune. In the study, three out of seven subjects experienced acute GvHD in the first 100 days. However, all subjects responded to standard-of care steroid treatment, and all three cases of GvHD resolved within 5-8 days." (3/20/2018)
- 2. According to Zacks Investment Research, "Fate Therapeutics, Inc. is a biopharmaceutical company. The company focused on the discovery and development of adult stem cell modulators to treat hematologic malignancies, lysosomal storage disorders and muscular dystrophies. Fate Therapeutics, Inc. is headquartered in San Diego, California. " (3/7/2018)
Are investors shorting Fate Therapeutics?
Fate Therapeutics saw a increase in short interest during the month of March. As of March 15th, there was short interest totalling 3,401,562 shares, an increase of 47.8% from the February 28th total of 2,301,328 shares. Based on an average trading volume of 1,116,342 shares, the short-interest ratio is currently 3.0 days. Currently, 7.6% of the company's stock are sold short.
Who are some of Fate Therapeutics' key competitors?
Some companies that are related to Fate Therapeutics include Adaptimmune Therapeutics (ADAP), Acorda Therapeutics (ACOR), Bavarian Nordic (BVNRY), La Jolla Pharmaceutical (LJPC), Coherus BioSciences (CHRS), Novavax (NVAX), Jounce Therapeutics (JNCE), Voyager Therapeutics (VYGR), Heska (HSKA), Mesoblast (MESO), EntreMed (CASI), BioCryst Pharmaceuticals (BCRX), PDL Biopharma (PDLI), Vericel (VCEL), Agenus (AGEN), Nightstar Therapeutics (NITE), Idera Pharmaceuticals (IDRA) and Solid Biosciences (SLDB).
Who are Fate Therapeutics' key executives?
Fate Therapeutics' management team includes the folowing people:
- William H. Rastetter Ph.D., Independent Chairman of the Board (Age 68)
- J. Scott Wolchko, President, Chief Executive Officer, Principal Executive Officer, Director (Age 44)
- John D. Mendlein Ph.D., Vice Chairman of the Board (Age 57)
- Jim Beitel, Senior Vice President - Corporate Development
- Daniel D. Shoemaker Ph.D., Chief Scientific Officer (Age 47)
- John Ferraro, Vice President - Clinical Operations
- Wendy Levin, Vice President - Clinical Development
- Walter Grubb, Vice President - Business Development
- Cindy Tahl J.D., General Counsel
- Stewart Abbot Ph.D., Chief Development Officer
Has Fate Therapeutics been receiving favorable news coverage?
Media stories about FATE stock have trended somewhat positive on Thursday, Accern Sentiment reports. The research firm identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Fate Therapeutics earned a coverage optimism score of 0.12 on Accern's scale. They also assigned news coverage about the biopharmaceutical company an impact score of 47.74 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
How do I buy shares of Fate Therapeutics?
Shares of FATE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Fate Therapeutics' stock price today?
One share of FATE stock can currently be purchased for approximately $11.32.
How big of a company is Fate Therapeutics?
Fate Therapeutics has a market capitalization of $608.99 million and generates $4.11 million in revenue each year. The biopharmaceutical company earns $-42,950,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. Fate Therapeutics employs 80 workers across the globe.
How can I contact Fate Therapeutics?
Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-875-1800 or via email at [email protected]
MarketBeat Community Rating for Fate Therapeutics (FATE)
MarketBeat's community ratings are surveys of what our community members think about Fate Therapeutics and other stocks. Vote "Outperform" if you believe FATE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FATE will underperform the S&P 500 over the long term. You may vote once every thirty days.
Fate Therapeutics (NASDAQ:FATE) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
8 Wall Street analysts have issued ratings and price targets for Fate Therapeutics in the last 12 months. Their average twelve-month price target is $16.1667, suggesting that the stock has a possible upside of 42.82%. The high price target for FATE is $20.00 and the low price target for FATE is $7.00. There are currently 2 hold ratings, 5 buy ratings and 1 strong buy rating for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.88 | 2.88 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
1 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
1 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $16.1667 | $14.6667 | $7.6667 | $7.20 |
| Price Target Upside: | 42.82% upside | 25.14% upside | 10.15% upside | 75.18% upside |
Fate Therapeutics (NASDAQ:FATE) Consensus Price Target History
Fate Therapeutics (NASDAQ:FATE) Analyst Ratings History
Show:
(Data available from 4/19/2016 forward)
Fate Therapeutics (NASDAQ:FATE) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Fate Therapeutics (NASDAQ FATE) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 9.89%
Institutional Ownership Percentage: 66.41%
Fate Therapeutics (NASDAQ FATE) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 10/16/2017 | Cindy Tahl | General Counsel | Sell | 8,091 | $3.85 | $31,150.35 | |  |
| 10/16/2017 | Daniel D Shoemaker | Insider | Sell | 13,225 | $3.87 | $51,180.75 | | |
| 11/23/2016 | Chris Storgard | Insider | Buy | 37,593 | $2.66 | $99,997.38 | 9,090 | |
| 11/23/2016 | William H Rastetter | Director | Buy | 375,939 | $2.66 | $999,997.74 | | |
| 6/12/2014 | Peter D Flynn | Insider | Sell | 6,488 | $7.00 | $45,416.00 | | |
| 6/10/2014 | Peter D Flynn | Insider | Sell | 3,305 | $7.00 | $23,135.00 | | |
| 5/1/2014 | Peter D Flynn | Insider | Sell | 9,793 | $7.07 | $69,236.51 | | |
| 4/4/2014 | Peter D Flynn | Insider | Sell | 5,889 | $8.00 | $47,112.00 | | |
| 4/2/2014 | Christian Weyer | Insider | Sell | 10,000 | $9.02 | $90,200.00 | | |
| 4/1/2014 | J Scott Wolchko | Insider | Sell | 20,000 | $9.64 | $192,800.00 | | |
| 3/31/2014 | Daniel D Shoemaker | CTO | Sell | 8,653 | $9.86 | $85,318.58 | | |
| 10/4/2013 | John Mendlein | Director | Buy | 16,667 | $6.00 | $100,002.00 | | |
| 10/4/2013 | Venture Fund Vi Lp Arch | Major Shareholder | Buy | 833,333 | $6.00 | $4,999,998.00 | | |
(Data available from 1/1/2013 forward)
Fate Therapeutics (NASDAQ FATE) News Headlines
| Source: |
|
Fate Therapeutics (NASDAQ:FATE) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Fate Therapeutics (NASDAQ:FATE) Income Statement, Balance Sheet and Cash Flow Statement
Fate Therapeutics (NASDAQ FATE) Stock Chart for Thursday, April, 19, 2018
Loading chart…
